Endovascular Therapy in Acute Isolated Posterior Cerebral Artery Occlusion

Author:

Abdelnaby Ramy,Mohamed Khaled Ashraf,ELgenidy Anas,Sonbol Yousef Tarek,Bedewy Mahmoud Mostafa,Aboutaleb Aya Moustafa,Dardeer Khaled Tarek,Heikal Hamed Amr,Gawish Hazem Maher,Nikoubashman Omid,Reich Arno,Pinho JoãoORCID

Abstract

Abstract Purpose Patients with isolated posterior cerebral artery occlusion (iPCAO) represent up to 6% of all acute ischemic stroke patients. Acute revascularization therapies for these patients were not tested in randomized controlled trials. The aim of this study was to evaluate outcomes of iPCAO patients who undergo endovascular treatment (EVT). Methods A systematic search of MEDLINE, Web of Science, CENTRAL, Scopus (inception—03/2022) was conducted for studies reporting 3‑month outcome, symptomatic intracranial hemorrhage (sICH) and/or successful recanalization in iPCAO patients who underwent EVT. Random effect meta-analyses for pooled proportions were calculated. Double-arm meta-analyses for comparison of outcomes of iPCAO patients treated with EVT with age-, sex- and NIHSS-matched iPCAO patients treated with best medical treatment only were performed. Results Fifteen studies reporting a total of 461 iPCAO patients who underwent EVT were included. Excellent and favorable 3‑month outcome proportions were 36% (95% confidence interval, CI 20–51%) and 57% (95% CI 40–73%), respectively. The 3‑month mortality was 9% (95% CI 5–13), sICH occurred in 1% (95% CI 0–2%), successful recanalization was achieved in 79% (95% CI 71–86%). No significant differences in favorable and excellent 3‑month outcomes, 3‑month mortality and symptomatic intracerebral hemorrhage were found between the groups of patients who underwent EVT and the group of patients who received best medical treatment only. Conclusion These results support the feasibility and safety of EVT in iPCAO, but do not show an outcome benefit with EVT compared to best medical treatment. Randomized trials are needed to evaluate treatment benefit of EVT in these patients.

Funder

RWTH Aachen University

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Radiology, Nuclear Medicine and imaging

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3